Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Personalized Medicine in Cardiovascular Diseases

  • Lee, Moo-Sik (Division of Cardiovascular Diseases, Mayo Clinic) ;
  • Flammer, Andreas. J. (Division of Cardiovascular Diseases, Mayo Clinic) ;
  • Lerman, Lilach. O. (Division of Nephrology and Hypertension, Mayo Clinic) ;
  • Lerman, Amir (Division of Cardiovascular Diseases, Mayo Clinic)
  • Published : 2012.09.30
⟨ Previous Next ⟩

Abstract

Personalized medicine is a novel medical model with all decisions and practices being tailored to individual patients in whatever ways possible. In the era of genomics, personalized medicine combines the genetic information for additional benefit in preventive and therapeutic strategies. Personalized medicine may allow the physician to provide a better therapy for patients in terms of efficiency, safety and treatment length to reduce the associated costs. There was a remarkable growth in scientific publication on personalized medicine within the past few years in the cardiovascular field. However, so far, only very few cardiologists in the USA are incorporating personalized medicine into clinical treatment. We review the concepts, strengths, limitations and challenges of personalized medicine with a particular focus on cardiovascular diseases (CVDs). There are many challenges from both scientific and policy perspectives to personalized medicine, which can overcome them by comprehensive concept and understanding, clinical application, and evidence based practices. Individualized medicine serves a pivotal role in the evolution of national and global healthcare reform, especially, in the CVDs fields. Ultimately, personalized medicine will affect the entire landscape of health care system in the near future.

Keywords

References

  1. Shapiro SD. Merging personalized medicine and biology of aging in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;184:864-6. https://doi.org/10.1164/rccm.201108-1486ED
  2. Aspinall MG, Hamermesh RG. Realizing the promise of personalized medicine. Harv Bus Rev 2007;85:108-17, 165.
  3. Piquette-Miller M, Grant DM. The art and science of personalized medicine. Clin Pharmacol Ther 2007;81:311-5. https://doi.org/10.1038/sj.clpt.6100130
  4. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001;7:201-4. https://doi.org/10.1016/S1471-4914(01)01986-4
  5. Lunshof JE, Pirmohamed M, Gurwitz D. Personalized medicine: decades away? Pharmacogenomics 2006;7:237-41. https://doi.org/10.2217/14622416.7.2.237
  6. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008;42:1017-25. https://doi.org/10.1345/aph.1L037
  7. The International HapMap Consortium. International HapMap Project. Available at: http://hapmap.ncbi.nlm.nih.gov. Accessed on: July 2, 2012.
  8. Guttmacher AE, Collins FS. Genomic medicine--a primer. N Engl J Med 2002;347:1512-20. https://doi.org/10.1056/NEJMra012240
  9. Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet 2011;12:217-44. https://doi.org/10.1146/annurev-genom-082410-101446
  10. Manace LC, Godiwala TN, Babyatsky MW. Genomics of cardiovascular disease. Mt Sinai J Med 2009;76:613-23. https://doi.org/10.1002/msj.20151
  11. Hudson TJ. Personalized medicine: a transformative approach is needed. CMAJ 2009;180:911-3. https://doi.org/10.1503/cmaj.1090199
  12. Collins F. Has the revolution arrived? Nature 2010;464:674-5. https://doi.org/10.1038/464674a
  13. Ku CS, Loy EY, Salim A, Pawitan Y, Chia KS. The discovery of human genetic variations and their use as disease markers: past, present and future. J Hum Genet 2010;55:403-15. https://doi.org/10.1038/jhg.2010.55
  14. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008;118:1590-605. https://doi.org/10.1172/JCI34772
  15. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009;154:277-87. https://doi.org/10.1016/j.trsl.2009.09.005
  16. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4. https://doi.org/10.1056/NEJMp1006304
  17. Bonter K, Desjardins C, Currier N, Pun J, Ashbury FD. Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open 2011;1:e000110. https://doi.org/10.1136/bmjopen-2011-000110
  18. Bates S. Progress towards personalized medicine. Drug Discov Today 2010;15:115-20. https://doi.org/10.1016/j.drudis.2009.11.001
  19. Wright CF, Kroese M. Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how? Hum Genet 2010; 127:125-34. https://doi.org/10.1007/s00439-009-0767-x
  20. Lewin J. Genetics, Your Heart and Your Future, The American College of Cardiology. Jan. 6, 2011. Available at: http://www.personalizedmedicinecoalition. org/sites/default/files/files/Jack%20Lewin.pdf.
  21. Jorgensen JT. A challenging drug development process in the era of personalized medicine. Drug Discov Today 2011;16:891-7. https://doi.org/10.1016/j.drudis.2011.09.010
  22. Zineh I, Pebanco GD, Aquilante CL, et al. Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann Pharmacother 2006; 40:639-44. https://doi.org/10.1345/aph.1G464
  23. US President's Council of Advisors on Science and Technology (PCAST). Priorities for Personalized Medicine. Washington DC: Executive Office of the President of United States;September 15, 2008.
  24. Aquilante C. Pharmacogenomics: The Promise of Personalized Medicine. Denver: University of Colorado;2007.
  25. Kasper DL, Braunwald E, Fauci AS, et al. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill Medical Publishing Division; 2008.
  26. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103:89-95. https://doi.org/10.1161/01.CIR.103.1.89
  27. Bristow M. New Frontiers in Personalized Medicine: Cardiovascular Research and Clinical Care. Personalized Medicine Coalition. Washington DC: The George Washington University;January 6, 2011.
  28. The National Forum for Heart Disease and Stroke Prevention. Update to A Public Health Action Plan to Prevent Heart disease and Stroke. Washington DC: Nexus; 2008.
  29. Ruben RJ. Otitis media: the application of personalized medicine. Otolaryngol Head Neck Surg 2011;145:707-12. https://doi.org/10.1177/0194599811419468
  30. Kardia SL, Modell SM, Peyser PA. Family-centered approaches to understanding and preventing coronary heart disease. Am J Prev Med 2003;24:143-51.
  31. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004;291: 2204-11. https://doi.org/10.1001/jama.291.18.2204
  32. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994;330:1041-6. https://doi.org/10.1056/NEJM199404143301503
  33. Arnar DO, Thorvaldsson S, Manolio TA, et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006;27:708-12. https://doi.org/10.1093/eurheartj/ehi727
  34. Fox CS, Parise H, D'Agostino RB Sr, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004;291:2851-5. https://doi.org/10.1001/jama.291.23.2851
  35. Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 2006;355: 138-47. https://doi.org/10.1056/NEJMoa052948
  36. Peyser PA, Bielak LF, Chu JS, et al. Heritability of coronary artery calcium quantity measured by electron beam computed tomography in asymptomatic adults. Circulation 2002;106:304-8. https://doi.org/10.1161/01.CIR.0000022664.21832.5D
  37. O'Donnell CJ, Chazaro I, Wilson PW, et al. Evidence for heritability of abdominal aortic calcific deposits in the Framingham Heart Study. Circulation 2002;106:337-41. https://doi.org/10.1161/01.CIR.0000022663.26468.5B
  38. Manolio TA, Boerwinkle E, O'Donnell CJ, Wilson AF. Genetics of ultrasonographic carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24:1567-77. https://doi.org/10.1161/01.ATV.0000138789.11433.c1
  39. O'Donnell CJ, Nabel EG. Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute: part I: the beginning of an era. Circ Cardiovasc Genet 2008;1:51-7. https://doi.org/10.1161/CIRCGENETICS.108.813337
  40. Arnett DK, Baird AE, Barkley RA, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007;115:2878-901. https://doi.org/10.1161/CIRCULATIONAHA.107.183679
  41. National Heart, Lung, and Blood Institute. Summary Report. National Heart, Lung, and Blood Institute Working Group on Atheroprotective Genes. March 29, 2000. Available at: http://www.nhlbi.nih.gov/meetings/ workshop/athro_rpt.htm. Accessed on: July 2, 2012.
  42. Nordlie MA, Wold LE, Kloner RA. Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol 2005;39:667-79. https://doi.org/10.1016/j.yjmcc.2005.06.006
  43. Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TO. A catalog of published genome-wide association studies. 2011. Available at: http:// www.genome.gov/gwastudies, Accessed on: May 27, 2011.
  44. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007;316:1491-3. https://doi.org/10.1126/science.1142842
  45. McCarthy JJ, Parker A, Salem R, et al. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet 2004;41:334-41. https://doi.org/10.1136/jmg.2003.016584
  46. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007; 316:1488-91. https://doi.org/10.1126/science.1142447
  47. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007;357:443-53. https://doi.org/10.1056/NEJMoa072366
  48. Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001;104:2641-4. https://doi.org/10.1161/hc4701.100910
  49. Thomas M, Lieberman J, Lal A. Desperately seeking microRNA targets. Nat Struct Mol Biol 2010;17:1169-74. https://doi.org/10.1038/nsmb.1921
  50. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95. https://doi.org/10.1067/mcp.2001.113989
  51. Genentech USA Inc. PERSONALIZED MEDICINE: Identifying the Appropriate Patient Through Biomarkers in Oncology. ManagedCare 2011; 20(7) Supplement 3.
  52. Roden DM, Altman RB, Benowitz NL, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006;145:749-57. https://doi.org/10.7326/0003-4819-145-10-200611210-00007
  53. Tester DJ, Ackerman MJ. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation 2011;123:1021-37. https://doi.org/10.1161/CIRCULATIONAHA.109.914838
  54. Shimizu W. Clinical impact of genetic studies in lethal inherited cardiac arrhythmias. Circ J 2008;72:1926-36. https://doi.org/10.1253/circj.CJ-08-0947
  55. Mateos-Cáceres PJ, García-Méndez A, López Farré A, et al. Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol 2004;44:1578-83. https://doi.org/10.1016/j.jacc.2004.06.073
  56. Sabatine MS, Liu E, Morrow DA, et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005;112:3868-75. https://doi.org/10.1161/CIRCULATIONAHA.105.569137
  57. Parguiña AF, Grigorian-Shamajian L, Agra RM, et al. Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study. PLoS One 2010;5:e13404. https://doi.org/10.1371/journal.pone.0013404
  58. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006;6:150-60. https://doi.org/10.1111/j.1600-6143.2005.01175.x
  59. Degoma EM, Rivera G, Lilly SM, Usman MH, Mohler ER 3rd. Personalized vascular medicine: individualizing drug therapy. Vasc Med 2011; 16:391-404. https://doi.org/10.1177/1358863X11422251
  60. Voora D, McLeod HL, Eby C, Gage BF. The pharmacogenetics of coumarin therapy. Pharmacogenomics 2005;6:503-13. https://doi.org/10.2217/14622416.6.5.503
  61. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-37. https://doi.org/10.1056/NEJMra020021
  62. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9. https://doi.org/10.1016/S0140-6736(98)04474-2
  63. US Food and Drug Administration. FDA approves updated warfarin ($Coumadin^{(R)}$) prescribing information. August 16, 2007. Available at: http://www.fda.gov/bbs/topics/news/2007/new01684.html.
  64. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363-8. https://doi.org/10.1161/01.CIR.0000153339.27064.14
  65. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115:1285-95.
  66. Ganz P, Vita JA. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 2003;108:2049-53. https://doi.org/10.1161/01.CIR.0000089507.19675.F9
  67. Rubinshtein R, Yang EH, Rihal CS, et al. Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur Heart J 2010;31:936-42. https://doi.org/10.1093/eurheartj/ehp459
  68. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010;31:1142-8. https://doi.org/10.1093/eurheartj/ehq010
  69. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008;117:2467-74. https://doi.org/10.1161/CIRCULATIONAHA.107.748574
  70. McCrea CE, Skulas-Ray AC, Chow M, West SG. Test-retest reliability of pulse amplitude tonometry measures of vascular endothelial function: implications for clinical trial design. Vasc Med 2012;17:29-36. https://doi.org/10.1177/1358863X11433188
  71. Monroe JB. A coalition to drive personalized medicine forward. Pers Med 2004;1:9-13. https://doi.org/10.1517/17410541.1.1.9
  72. Kramer BS, Croswell JM. Cancer screening: the clash of science and intuition. Annu Rev Med 2009;60:125-37. https://doi.org/10.1146/annurev.med.60.101107.134802
  73. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-37. https://doi.org/10.1056/NEJMra020021
  74. Johnson JA, Lima JJ. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 2003; 13:525-34. https://doi.org/10.1097/00008571-200309000-00001
  75. Personalized Medicine Coalition. The case for Personalized Medicine. 3rd ed. New York: Personalized Medicine Coalition;2009.
  76. Califf RM, Ginsburg GS. Organizational improvements to enhance modern clinical epidemiology. JAMA 2008;300:2300-2. https://doi.org/10.1001/jama.2008.638

Cited by

  1. Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Afford New Opportunities in Inherited Cardiovascular Disease Modeling vol.2016, pp.None, 2012, https://doi.org/10.1155/2016/3582380
  2. Ride the wave of genomic health care: a new challenge in nursing vol.12, pp.5, 2012, https://doi.org/10.12968/bjca.2017.12.5.215
  3. Personalized medicine in inflammatory cardiomyopathy vol.15, pp.2, 2018, https://doi.org/10.2217/pme-2017-0074
  4. Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy vol.3, pp.2, 2012, https://doi.org/10.1002/adtp.201900100
  5. Patient Management in Aortic Stenosis: Towards Precision Medicine through Protein Analysis, Imaging and Diagnostic Tests vol.9, pp.8, 2012, https://doi.org/10.3390/jcm9082421
  6. On the Clinical Pharmacology of Reactive Oxygen Species vol.72, pp.4, 2012, https://doi.org/10.1124/pr.120.019422
  7. The Role of Computer Skills in Personal Health Record Adoption Among Patients With Heart Disease: Multidimensional Evaluation of Users Versus Nonusers vol.8, pp.3, 2012, https://doi.org/10.2196/19191
  8. Cardiovascular Diseases and Pharmacomicrobiomics: A Perspective on Possible Treatment Relevance vol.9, pp.10, 2012, https://doi.org/10.3390/biomedicines9101338
  9. Long Non-Coding RNAs in Cardiovascular Diseases: Potential Function as Biomarkers and Therapeutic Targets of Exercise Training vol.7, pp.4, 2012, https://doi.org/10.3390/ncrna7040065